Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced and Metastatic Urothelial Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 166Capecitabine 112Fluorouracil 95Docetaxel 85Cisplatin 84S 1 (combination) 83Leucovorin 64Paclitaxel 58Irinotecan 56pembrolizumab 36sintilimab 34Trastuzumab 34apatinib 30Bevacizumab 21Surgical Procedures, Operative 19Radiotherapy 19titanium silicide 17camrelizumab 17Nivolumab 17Ramucirumab 16Drug Therapy 15Hyperthermic Intraperitoneal Chemotherapy 14Folfox protocol 14Epirubicin 14tislelizumab 13Neoadjuvant Therapy 12Cetuximab 12XELOX 10Tegafur 10Carboplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Stomach Neoplasms × futibatinib × Clear all
NCT04189445 2025-10-08

Futibatinib in Patients With Specific FGFR Aberrations

Taiho Oncology, Inc.

Phase 2 Terminated
115 enrolled 19 charts
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡